Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NRT-01
ChiCTR-OIC-17011275Phase 2Not yet recruiting
- Sponsor
- Nanjing Drum-Tower Hospital
- Start
- Jun 2017
- Modality
- Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Neoantigen-reactive T cells in Nonhematologic neoplasms, sponsored by Nanjing Drum-Tower Hospital. Primary endpoints: treatment-related adverse events and objective response rate. Planned start Jun 2017; status: not yet recruiting.
02
Drugs
Neoantigen-reactive T cells
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on ChiCTR-OIC-17011275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OIC-17011275.